Omeros Corporation's Eye-Popping Surge

Biotech Omeros Corporation has been on a tear since the start of September. With momentum building from a product headed for a Food and Drug Administration review and analyst upgrades, shares are up almost 16% today and have more than doubled in the last month.

OMER Chart
OMER Chart

OMER data by YCharts.

In the following video, from The Motley Fool's health-care show Market Checkup, analyst Max Macaluso discusses the market's enthusiasm about Omeros and the opportunities and risks investors should watch for.

Investing in biotechs
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Note: This video was recorded on Oct. 2, 2013.

The article Omeros Corporation's Eye-Popping Surge originally appeared on

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.